FINNENCE ▪ THE WIRE FILE
THE WIRE · № 87916
SEC Filing■ Mixed
AMD filed 4 on 2026-10-19
KINDSEC Filing
DIRECTION■ Mixed
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
THE MACHINE IS STILL READING THIS ITEM — ANALYSIS LANDS WITHIN MINUTES OF INGESTION.
FULL DISPATCH
AMD (CIK 0001622864) filed a 4 on 2026-10-19.
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
SUBJECTAdvanced Micro Devices · AMD
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes — Eli Lilly and Company2026-10-19 12:00 UTC
New Phase 3 trial: A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes — Eli Lilly and Company2026-10-19 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever — R-Pharm2026-10-19 12:00 UTC
New Phase 3 trial: Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever — R-Pharm2026-10-19 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2) — Pfizer2026-10-19 12:00 UTC
New Phase 3 trial: A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2) — Pfizer2026-10-19 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer — CSPC Megalith Biopharmaceutical Co.,Ltd.2026-10-19 12:00 UTC
New Phase 3 trial: A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer — CSPC Megalith Biopharmaceutical Co.,Ltd.2026-10-19 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer — Jiangsu Simcere Pharmaceutical Co., Ltd.2026-10-19 12:00 UTC
New Phase 3 trial: A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer — Jiangsu Simcere Pharmaceutical Co., Ltd.2026-10-19 12:00 UTC
→INFERENCEfilings generate company commentary
New Phase 3 trial: Efficacy and Safety of DNN.63.18.040 for the Treatment of Moderate to Severe Pain — Ache Laboratorios Farmaceuticos S.A.2026-10-19 12:00 UTC
New Phase 3 trial: Efficacy and Safety of DNN.63.18.040 for the Treatment of Moderate to Severe Pain — Ache Laboratorios Farmaceuticos S.A.2026-10-19 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.